Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 1 20 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS 1 20 versus PHILITH.
GILDESS 1/20 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (GnRH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
1 mg orally once daily
None Documented
None Documented
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive